# Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

> **NCT02983006** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 12 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** DS-8273a
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02983006
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2019-12-23
- **Final completion:** 2021-01-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-10-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02983006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02983006, "Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02983006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*